Linked Life Data

17322624

Source:http://linkedlifedata.com/resource/pubmed/id/17322624

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17322624rdf:typepubmed:Citationlld:pubmed
pubmed-article:17322624lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:17322624lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:17322624lifeskim:mentionsumls-concept:C0596972lld:lifeskim
pubmed-article:17322624lifeskim:mentionsumls-concept:C0235480lld:lifeskim
pubmed-article:17322624lifeskim:mentionsumls-concept:C1623258lld:lifeskim
pubmed-article:17322624lifeskim:mentionsumls-concept:C0016229lld:lifeskim
pubmed-article:17322624lifeskim:mentionsumls-concept:C0016385lld:lifeskim
pubmed-article:17322624lifeskim:mentionsumls-concept:C0231220lld:lifeskim
pubmed-article:17322624lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:17322624lifeskim:mentionsumls-concept:C1521743lld:lifeskim
pubmed-article:17322624lifeskim:mentionsumls-concept:C0181904lld:lifeskim
pubmed-article:17322624lifeskim:mentionsumls-concept:C1704646lld:lifeskim
pubmed-article:17322624lifeskim:mentionsumls-concept:C0728873lld:lifeskim
pubmed-article:17322624pubmed:issue3lld:pubmed
pubmed-article:17322624pubmed:dateCreated2007-2-26lld:pubmed
pubmed-article:17322624pubmed:abstractTextA double-blind, randomized, parallel-group, placebo-controlled trial was conducted in patients with paroxysmal atrial fibrillation or flutter (PAF/PAFL) experiencing 2 or more episodes of symptomatic PAF/PAFL during a 28-day observation period to determine the dose-response effect and safety of flecainide.lld:pubmed
pubmed-article:17322624pubmed:languageenglld:pubmed
pubmed-article:17322624pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17322624pubmed:citationSubsetIMlld:pubmed
pubmed-article:17322624pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17322624pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17322624pubmed:statusMEDLINElld:pubmed
pubmed-article:17322624pubmed:monthMarlld:pubmed
pubmed-article:17322624pubmed:issn1346-9843lld:pubmed
pubmed-article:17322624pubmed:authorpubmed-author:OgawaSatoshiSlld:pubmed
pubmed-article:17322624pubmed:authorpubmed-author:InoueHiroshiHlld:pubmed
pubmed-article:17322624pubmed:authorpubmed-author:AtarashiHirot...lld:pubmed
pubmed-article:17322624pubmed:authorpubmed-author:HamadaChikuma...lld:pubmed
pubmed-article:17322624pubmed:authorpubmed-author:Flecainide...lld:pubmed
pubmed-article:17322624pubmed:issnTypePrintlld:pubmed
pubmed-article:17322624pubmed:volume71lld:pubmed
pubmed-article:17322624pubmed:ownerNLMlld:pubmed
pubmed-article:17322624pubmed:authorsCompleteYlld:pubmed
pubmed-article:17322624pubmed:pagination294-300lld:pubmed
pubmed-article:17322624pubmed:meshHeadingpubmed-meshheading:17322624...lld:pubmed
pubmed-article:17322624pubmed:meshHeadingpubmed-meshheading:17322624...lld:pubmed
pubmed-article:17322624pubmed:meshHeadingpubmed-meshheading:17322624...lld:pubmed
pubmed-article:17322624pubmed:meshHeadingpubmed-meshheading:17322624...lld:pubmed
pubmed-article:17322624pubmed:meshHeadingpubmed-meshheading:17322624...lld:pubmed
pubmed-article:17322624pubmed:meshHeadingpubmed-meshheading:17322624...lld:pubmed
pubmed-article:17322624pubmed:meshHeadingpubmed-meshheading:17322624...lld:pubmed
pubmed-article:17322624pubmed:meshHeadingpubmed-meshheading:17322624...lld:pubmed
pubmed-article:17322624pubmed:meshHeadingpubmed-meshheading:17322624...lld:pubmed
pubmed-article:17322624pubmed:meshHeadingpubmed-meshheading:17322624...lld:pubmed
pubmed-article:17322624pubmed:meshHeadingpubmed-meshheading:17322624...lld:pubmed
pubmed-article:17322624pubmed:meshHeadingpubmed-meshheading:17322624...lld:pubmed
pubmed-article:17322624pubmed:meshHeadingpubmed-meshheading:17322624...lld:pubmed
pubmed-article:17322624pubmed:meshHeadingpubmed-meshheading:17322624...lld:pubmed
pubmed-article:17322624pubmed:year2007lld:pubmed
pubmed-article:17322624pubmed:articleTitleDose-response effect of flecainide in patients with symptomatic paroxysmal atrial fibrillation and/or flutter monitored with trans-telephonic electrocardiography: a multicenter, placebo-controlled, double-blind trial.lld:pubmed
pubmed-article:17322624pubmed:affiliationDepartment of Internal Medicine, Nippon Medical School, Tama-Nagayama Hospital, Japan. atarashi@nms.ac.jplld:pubmed
pubmed-article:17322624pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17322624pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:17322624pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:17322624pubmed:publicationTypeMulticenter Studylld:pubmed